Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma.

Kim, Seok Jin; Ryu, Kyung Ju; Park, Bon; Yoon, Sang Eun; Cho, Junhun; Park, Yoon; Kim, Won Seog

Kim, Seok Jin; Ryu, Kyung Ju; Park, Bon; Yoon, Sang Eun; Cho, Junhun; Park, Yoon; Kim, Won Seog.

Afiliación

Kim SJ; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
Ryu KJ; Department of Health Sciences and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul 06351, Republic of Korea.
Park B; Department of Health Sciences and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul 06351, Republic of Korea.
Yoon SE; Department of Health Sciences and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul 06351, Republic of Korea.
Cho J; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
Park Y; Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
Kim WS; Biomedical Research Institute, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.

Cancers (Basel) ; 14(22)2022 Nov 16.

Article en En | MEDLINE | ID: mdl-36428710

Palabras clave

exosome; extranodal NK/T-cell lymphoma; pembrolizumab; soluble PD-L1

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google